Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.

Additional locations may be listed on ClinicalTrials.gov for NCT05797831.

Trial PhasePhase II/III

Trial Typetreatment

Lead OrganizationKartos Therapeutics, Inc.

• Primary IDKRT-232-118
• Secondary IDsNCI-2024-03038, ENGOT en-21, GOG-3089
• ClinicalTrials.gov IDNCT05797831